Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O60895
UPID:
RAMP2_HUMAN
Alternative names:
Calcitonin-receptor-like receptor activity-modifying protein 2
Alternative UPACC:
O60895; A7L9S6; K7EMD3; Q8N1F2
Background:
Receptor activity-modifying protein 2 (RAMP2) plays a crucial role in cellular signaling by transporting the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. It also functions as a receptor for adrenomedullin (AM) in conjunction with CALCRL, highlighting its importance in physiological processes.
Therapeutic significance:
Understanding the role of Receptor activity-modifying protein 2 could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways suggests its potential as a target for drug discovery, aiming to modulate its function for therapeutic benefits.